Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (GB:0HFQ)
LSE:0HFQ
AnaptysBio (0HFQ) Share Price & Analysis
0 Followers
0HFQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.80 - $38.72
Previous Close$38.72
Volume1.00
Average Volume (3M)140.00
Market Cap
$1.01B
Enterprise Value$675.15M
Total Cash (Recent Filing)$354.67M
Total Debt (Recent Filing)$17.39M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 05, 2024EPS Estimate
-$1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,318,644
10 Day Avg. Volume0
30 Day Avg. Volume140
Standard Deviation0.24
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)13.72
Price to Sales (P/S)40.17
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.40
Enterprise Value/Gross Profit39.35
Enterprise Value/Ebitda-4.43
Forecast
1Y Price Target
$58.80Price Target Upside51.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsIn Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, inflammatory cytokine secretion and PD-1(high) T cells and demonstrated favorable safety.
Market PotentialRosnilimab could be a best-in-class PD-1 agonist, in analysts' view.
Product DifferentiationANB032 offers a differentiated pathway, targeting a broad spectrum of immune cells that have been implicated in AD progression including Th1/Th2/Th17/Th22 and potentially DCs.
Bears Say
Clinical TrialsJNJ evaluated it in a Ph1 RA trial, but JNJ never disclosed those results and did not advance it in RA.
Investor ConcernsSome investors had feared the worst-case scenario that LLY could have dropped it in conjunction with its 1Q results.
Uncertainty In UpdatesWe do not know if LLY will provide any updates on peresolimab in conjunction with 1Q financial results on Apr. 30.
---
Options Prices
Currently, No data available
---
Ownership Overview
68.90% Insiders
15.83% Mutual Funds
13.28% Other Institutional Investors
1.99% Public Companies and
Individual Investors
0HFQ FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest share price was $13.80 and its highest was $38.72 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Aug 05, 2024 which is in 9 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on May 09, 2024. The company reported -$1.64 earnings per share for the quarter, missing the consensus estimate of -$1.566 by -$0.074.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.04.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 27,318,644 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.64 in its last earnings report, missing expectations of -$1.566. Following the earnings report the stock price went down -4.344%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 11M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.80 (51.86% Upside)
$58.80 (51.86% Upside)
Blogger Sentiment
Bullish
GB:0HFQ Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.23%
12-Months-Change
Fundamentals
Return on Equity
-136.73%
Trailing 12-Months
Asset Growth
-26.45%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
0HFQ Stock 12 Month Forecast
Average Price Target
$58.80
▲(51.86% Upside)
Technical Analysis
Best Analysts Covering 0HFQ
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
-29.24%
upgraded a buy rating 9 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -29.24% per trade.
---